16 September 2026 editorial review · Trial
iLet Bionic Pancreas (insulin-only) pivotal trial: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Primary-agent trial review — 16 September 2026
Assessment: Summary, current status, primary endpoint and key eligibility compared with the current registry. No additional discrepancy confirmed in that comparison. Historical outcome details beyond the primary sources explicitly discussed in the specialist ledgers were not all independently reverified.
Registry: NCT04200313; COMPLETED; updated 2025-02-20; enrollment 440 (ACTUAL); results posted.
Endpoint comparison: HbA1c (13 weeks).
Sources for this record: Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes. (peer-reviewed); Jaeb Center for Health Research. The Insulin-Only Bionic Pancreas Pivotal Trial: Testing the iLet in Adults and Children With Type 1 Diabetes. ClinicalTrials.gov (NCT04200313) (registry); Beta Bionics. The iLet Bionic Pancreas Significantly Reduced HbA1c and Improved Time in Range vs Standard of Care. Healio / Beta Bionics press release (2022) (news); Positive Impact of the Bionic Pancreas on Diabetes Control in Youth 6-17 Years Old with Type 1 Diabetes: A Multicenter Randomized Trial. (peer-reviewed); Boston University. FDA Clears Bionic Pancreas Developed in BU Lab for People with Type 1 Diabetes. BU News (2023) (community).
Limits: Source access and review depth vary. Registry fields establish the registered study, not clinical benefit, product approval or current local access. Cited-source reachability alone was not treated as verification of its claims.
Selected historical trial audit
Correction: Main randomized comparison is 326 participants (219 iLet with aspart/lispro, 107 standard care), distinct from the registry's 440 across the broader protocol, including faster aspart. Corrected summary denominator and pediatric companion-analysis wording; removed an eligibility maximum derived from observed age rather than the registry. HbA1c adjusted difference −0.5 percentage points, CGM low-glucose noninferiority and severe-event rates agree with the primary abstract. No DKA applies to that main comparison, not automatically to every protocol cohort.
Sources: Primary NEJM report, registry.
Limit: Secondary subgroup equality and every faster-aspart outcome were not independently re-reviewed. Nonsignificant severe-hypoglycemia comparison does not establish identical risks.